Financing channel feed – Endpoints News

Financing channel feed

Tocagen shoots for $86 million IPO, spotlighting a high-risk shot at a quick OK for brain cancer therapy

9 years ago

Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics

9 years ago

Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition

9 years ago

OrbiMed doubling down on Asia biotech bets with $450M fund

9 years ago

Alta Partners sketches plans to raise $200M for its next life sciences venture fund

9 years ago

Going big: Biotech vets blast off with Arrakis on a new journey of RNA exploration

9 years ago

Looking to an IPO? Rhythm raises $41M to pay for pivotal trials

9 years ago

Serono spinout grabs a $31M round for a pair of proof-of-concept Parkinson’s trials

9 years ago

Biotech dealmaker Ramaswamy raises another $55M for Axovant

9 years ago

Versant backs a rebooted Tarveda with $30M round for pipeline development

9 years ago

Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford

9 years ago

Jounce’s Cinderella story now includes a $102M IPO chapter

9 years ago

Singapore investors at Temasek grab an $800M stake in Google’s Verily

9 years ago

Venrock stocks up on $450M Fund 8 as it prepares a new string of biotech deals

9 years ago

An early arrival among '17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play

9 years ago

Vision or voodoo? Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals

9 years ago

The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like

9 years ago

Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases

9 years ago

Neon Therapeutics bags a $70M round for early-stage neoantigen research

9 years ago

Digitalis makes its debut with $100M fund and a yen for ‘deeply technical people’

9 years ago

Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts

9 years ago

Chinese VC syndicates wager $172M on Ascentage and Ascletis, flagging a new trend

9 years ago

Jounce rings out the old year with a $75M IPO bid for the New Year

9 years ago

Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic

9 years ago

First page Previous page 141 142 143144145 146 Next page Last page